Exicure (XCUR) Competitors $7.45 +0.09 (+1.22%) Closing price 08/8/2025 03:57 PM EasternExtended Trading$7.41 -0.04 (-0.54%) As of 08/8/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. CRBU, EPRX, CTMX, ELDN, TVGN, SXTC, OGI, LYEL, CYBN, and RAPTShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Caribou Biosciences (CRBU), Eupraxia Pharmaceuticals (EPRX), CytomX Therapeutics (CTMX), Eledon Pharmaceuticals (ELDN), Semper Paratus Acquisition (TVGN), China SXT Pharmaceuticals (SXTC), Organigram Global (OGI), Lyell Immunopharma (LYEL), Cybin (CYBN), and Rapt Therapeutics (RAPT). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Its Competitors Caribou Biosciences Eupraxia Pharmaceuticals CytomX Therapeutics Eledon Pharmaceuticals Semper Paratus Acquisition China SXT Pharmaceuticals Organigram Global Lyell Immunopharma Cybin Rapt Therapeutics Exicure (NASDAQ:XCUR) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership. Which has preferable earnings and valuation, XCUR or CRBU? Exicure has higher earnings, but lower revenue than Caribou Biosciences. Exicure is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K94.17-$9.70M-$3.82-1.95Caribou Biosciences$9.99M16.11-$149.10M-$1.62-1.07 Does the media favor XCUR or CRBU? In the previous week, Exicure had 5 more articles in the media than Caribou Biosciences. MarketBeat recorded 5 mentions for Exicure and 0 mentions for Caribou Biosciences. Exicure's average media sentiment score of 0.25 beat Caribou Biosciences' score of 0.00 indicating that Exicure is being referred to more favorably in the media. Company Overall Sentiment Exicure Neutral Caribou Biosciences Neutral Do analysts rate XCUR or CRBU? Caribou Biosciences has a consensus target price of $6.67, suggesting a potential upside of 285.36%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is XCUR or CRBU more profitable? Exicure has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,490.84%. Caribou Biosciences' return on equity of -55.70% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -219.60% -82.03% Caribou Biosciences -1,490.84%-55.70%-45.35% Do insiders & institutionals have more ownership in XCUR or CRBU? 42.8% of Exicure shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 3.9% of Exicure shares are held by company insiders. Comparatively, 8.3% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, XCUR or CRBU? Exicure has a beta of 3.67, suggesting that its stock price is 267% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.55, suggesting that its stock price is 155% more volatile than the S&P 500. SummaryCaribou Biosciences beats Exicure on 10 of the 16 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.07M$2.99B$5.52B$9.72BDividend YieldN/A2.42%4.60%4.12%P/E Ratio-1.9217.2130.0124.75Price / Sales94.17310.81450.0597.82Price / CashN/A41.7736.7758.47Price / Book6.657.318.185.59Net Income-$9.70M-$54.43M$3.26B$265.99M7 Day Performance5.67%0.01%6.13%5.06%1 Month Performance2.34%0.63%0.07%0.61%1 Year Performance1,305.40%8.41%36.31%22.82% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure0.9861 of 5 stars$7.45+1.2%N/A+1,305.4%$47.07M$500K-1.9250News CoverageEarnings ReportUpcoming EarningsGap UpCRBUCaribou Biosciences2.4304 of 5 stars$2.06-2.1%$8.50+313.6%-10.8%$192.98M$9.99M-1.28100Upcoming EarningsGap UpEPRXEupraxia Pharmaceuticals2.7466 of 5 stars$5.33-1.0%$11.00+106.6%+96.3%$191.49MN/A-7.0129CTMXCytomX Therapeutics3.9906 of 5 stars$2.38-0.6%$5.75+142.1%+95.8%$190.67M$138.10M4.93170News CoverageGap DownELDNEledon Pharmaceuticals1.6458 of 5 stars$3.19-2.0%$10.00+214.0%+3.4%$190.12MN/A-1.5110Gap UpTVGNSemper Paratus Acquisition3.6725 of 5 stars$1.01+1.2%$10.00+895.0%+40.0%$184.81MN/A0.003SXTCChina SXT Pharmaceuticals0.8107 of 5 stars$1.59+0.3%N/A-80.5%$183.79M$1.74M0.0090OGIOrganigram Global1.1809 of 5 stars$1.37-1.1%N/A-1.7%$182.95M$117.47M13.65860Upcoming EarningsLYELLyell Immunopharma3.315 of 5 stars$11.71+3.0%$15.00+28.1%-64.1%$180.42M$60K-0.47270CYBNCybin2.8356 of 5 stars$7.56-1.6%$85.00+1,024.3%N/A$177.99MN/A-1.7250Positive NewsRAPTRapt Therapeutics4.2876 of 5 stars$10.61-1.4%$20.57+93.9%-46.0%$175.49M$1.53M-0.5580News CoverageEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Caribou Biosciences Alternatives Eupraxia Pharmaceuticals Alternatives CytomX Therapeutics Alternatives Eledon Pharmaceuticals Alternatives Semper Paratus Acquisition Alternatives China SXT Pharmaceuticals Alternatives Organigram Global Alternatives Lyell Immunopharma Alternatives Cybin Alternatives Rapt Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XCUR Stock Alerts